Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:4:75-84.
doi: 10.2147/IJWH.S28103. Epub 2012 Mar 13.

Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery

Josep L Carbonell Esteve  1 , Ana M Riverón, Mariela Cano, Alma I Ortiz, Aleta Valle, Carlos S Texidó, Giuseppe Tomasi
Affiliations

Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery

Josep L Carbonell Esteve et al. Int J Womens Health. 2012.

Abstract

Objectives: To evaluate the efficacy and safety of 2.5 mg and 5 mg mifepristone during 3 months for the treatment of uterine fibroids before surgery.

Design: Multicenter randomized clinical trial.

Locations: Eusebio Hernández Hospital, Havana, Cuba and the Alemán Hospital, Managua, Nicaragua.

Subjects: Included in the study were 146 women with symptomatic uterine fibroids.

Treatment: GROUP I: half a tablet of 5 mg (2.5 mg) mifepristone taken orally every 24 hours, and Group II: one tablet of 5 mg mifepristone taken orally every 24 hours over a period of 3 months in both groups. Two endometrial biopsies were performed. VARIABLES TO EVALUATE EFFICACY: Increase in average hemoglobin, changes in fibroid and uterine volume, and symptomatic improvement.

Results: The average hemoglobin at the end of treatment was 0.6 g/dL greater in the 5 mg mifepristone group (P = 0.033). In both groups there were similar reductions in fibroid volumes. Clinical improvement was more significant in the 5 mg group.

Conclusion: The dose to be used should be 5 mg.

Keywords: antiprogestins; fibroid; leiomyoma; mifepristone.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart for the trial.
See this image and copyright information in PMC

References

    1. Day BD, Dunson DB, Hill MC, Coousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100–107. - PubMed
    1. Wegienka G, Baird DD, Hertz-Piccioto I, et al. Self-reported heavy bleeding associated with uterine leiomyomata. Obstet Gynecol. 2003;101(3):431–437. - PubMed
    1. Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z, Peterson HB. Hysterectomy in the United States, 1988–1990. Obstet Gynecol. 1994;83(4):549–555. - PubMed
    1. Wilson EA, Yang F, Reese E. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues. Obstet Gynecol. 1980;55(1):20–24. - PubMed
    1. Andersen J. Factors in fibroid growth. Baillieres Clin Obstet Gynaecol. 1998;12(2):225–243. - PubMed